These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32104020)

  • 1. Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder.
    Yan T; Greene M; Chang E; Houle CR; Tarbox MH; Broder MS
    Clinicoecon Outcomes Res; 2020; 12():81-89. PubMed ID: 32104020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data.
    Niu X; Dennen S; Dembek C; Laubmeier K; Liu Y; Veeranki P; Tocco M; Williams GR
    Curr Ther Res Clin Exp; 2021; 94():100629. PubMed ID: 34306269
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    Clinicoecon Outcomes Res; 2019; 11():741-755. PubMed ID: 31824181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data.
    Niu X; Veeranki P; Dennen S; Dembek C; Laubmeier K; Liu Y; Williams GR; Loebel A
    Curr Med Res Opin; 2021 May; 37(5):839-846. PubMed ID: 33682547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
    Broder MS; Greene M; Chang E; Hartry A; Yan T; Yermilov I
    J Med Econ; 2019 Jan; 22(1):63-70. PubMed ID: 30376745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
    J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data.
    Halpern R; Nadkarni A; Kalsekar I; Nguyen H; Song R; Baker RA; Nelson JC
    Ann Pharmacother; 2013; 47(7-8):933-45. PubMed ID: 23715066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study.
    Kadakia A; Dembek C; Liu Y; Dieyi C; Williams GR
    J Med Econ; 2021; 24(1):1212-1220. PubMed ID: 34647502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.
    Nadkarni A; Kalsekar I; You M; Forbes R; Hebden T
    Clinicoecon Outcomes Res; 2013; 5():49-57. PubMed ID: 23378778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns, health care resource utilization, and costs associated with use of atypical antipsychotics as first vs subsequent adjunctive treatment in major depressive disorder.
    Jain R; Laliberté F; Germain G; Mahendran M; Higa S; Harrington A; Parikh M
    J Manag Care Spec Pharm; 2023 Aug; 29(8):896-906. PubMed ID: 37523314
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data.
    Yermilov I; Greene M; Chang E; Hartry A; Yan T; Broder MS
    Adv Ther; 2018 Dec; 35(12):2138-2151. PubMed ID: 30456519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
    Ng-Mak D; Halpern R; Rajagopalan K; Loebel A
    Curr Med Res Opin; 2019 Feb; 35(2):211-219. PubMed ID: 29625538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
    Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
    Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis.
    Newcomer JW; Ng-Mak D; Rajagopalan K; Loebel A
    BMC Health Serv Res; 2018 Apr; 18(1):243. PubMed ID: 29618351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach.
    Saylan M; Treur MJ; Postema R; Dilbaz N; Savas H; Heeg BM; Drost PB
    Value Health Reg Issues; 2013; 2(2):171-180. PubMed ID: 29702862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.